CAIN BROTHERS
A division of
KeyBanc Capital Markets

July 6, 2026

Industry Insights

Healthcare Market Report



Banker Commentary:

Pharma Services M&A: Market Access and Potential Business Model Impact From AI Take Center Stage

Banker Commentary

Contents

Pharma Services M&A: Market Access and Potential Business Model Impact From AI Take Center Stage

Banker Commentary by Jason Moran

It would be easy to read the 2025 headlines and conclude that pharma services M&A is booming. Transaction value reached a record — more than $25 billion across the sector — and 2026 has opened with activity running at nearly twice the value of early 2025. But these statistics mask a more nuanced reality. Deal count has fallen, continuing a decline of ~10% annually from the 2023 peak. On the larger side, pharma services M&A has been narrowly focused on a handful of larger premium platforms, and, on the smaller side, on a few select market segments, especially Market Access. And, importantly, consideration of potential AI-related business model disruption (both positive and negative) has become a central and ubiquitous pillar of buyer diligence.

CDMOs, CROs, and the Structural Tailwinds

Contract manufacturing enters 2026 with the strongest tailwinds in years. The BIOSECURE Act, signed in December 2025, will reward domestic production as sponsors de-risk supply chains, while tariff uncertainty drives tech transfers, dual-sourcing, and new U.S. and European capacity. Demand for sterile injectables remains acute given the GLP-1 build-out, and CDMO multiples have recovered from their 2024 trough to near pre-pandemic levels. On the research side, the story is a healthy one —IQVIA, ICON, PPD (Themo Fisher), and Medpace posted strong 2025 results as biotech funding stabilized, while Thermo Fisher's ~$8.9 billion purchase of Clario and Charles River's early-2026 divestitures show that focus now drives M&A activity as much as scale.

Market Access Steps in the Spotlight

For the past 18 months, Market Access has been the most dynamic area of pharma services M&A. Market Access, which represents a ~$5 billion market, growing at 10%+, includes services relating to strategies, policies, and negotiations that ensure that a pharmaceutical product is commercially available, fully reimbursed, and accessible to the patients who need it. The list of M&A transactions is extensive: Baird Capital's acquisition of Newmarket Strategy, FIECON's acquisition by Herspiegel, Stratevi's acquisition by Minds + Assembly, Hayden's acquisition by BGB Group, Access Infinity's acquisition by CBPE Capital (a Cain Brothers deal) and the acquisition of Stratis Group by Nexus Health (Lockwood). In general, multiples for these deals have been robust as the investment logic for Market Access is compelling: these businesses are asset-light, with recurring and sticky revenue, are growing steadily, and sit at critical, high-value decision points. Additionally, for platform players, Market Access enables the integration of adjacent service areas, creating synergistic, end-to-end solutions that unlock tangible opportunities to capture additional TAM.

AI Enters Upstream and Moves Downstream

AI has moved from pilot to budget line in the pharma world, but it is not arriving everywhere at once—its adoption is following a clear path through the value chain. The entry point has been upstream, in discovery and clinical development, where the data is richest, the workflows most quantifiable, and the payoff from a successful model most immediate; there, AI is already compressing timelines and improving trial predictability.

Leading the way is Eli Lilly. In partnership with NVIDIA, Lilly is building what it calls the most powerful supercomputer owned and operated by a pharmaceutical company—an "AI factory" that can train models on millions of experiments—and is opening proprietary models, built on its own data, to the broader ecosystem through its TuneLab platform**.** Where Lilly leads, the services firms that supply the laboratory infrastructure and implementation services are following.

Underpinning the shift is the modernization of the lab data layer itself: Laboratory information management systems (LIMS) are migrating to the cloud and acquiring AI capabilities—more than half of laboratories now report using AI tools—turning accumulated data into training fuel. Companies like Astrix (a Quad-C portfolio company) and Slipsteam (a GreyLion portfolio company) are excellent examples of organizations that are benefiting from AI-related digital transformation in LIMS.

AI has also reached the pharma back office, where automation of pharmacovigilance and documentation is cutting manual effort by half or more. It is now arriving in commercialization services—the last and largest frontier. In Medical Communications, generative AI can draft publication-ready manuscripts, assemble summaries, and produce field materials in minutes, compressing literature reviews from weeks to hours. In Market Access, AI-driven predictive analytics forecast payer coverage and reimbursement outcomes by mining historical decisions, and agentic platforms are beginning to orchestrate Medical Affairs workflows rather than merely informing them. For buyers considering acquisitions in commercialization services, however, opinions differ as to whether AI will be accretive or dilutive to business models over the medium term.

Where This Leaves Us

The M&A setup for the remainder of 2026 and the first part of 2027 is constructive but selective. Macro drivers include onshoring, biotech funding recovery, and a significant backlog of sponsor platform exits. Premium multiples will accrue to platforms that pair scale and integrated capabilities and to niche players with specialized, best-of-breed competencies. Also, perception of AI-related business model risk (and opportunity) is playing heavily into all investment decisions. For sellers weighing a process, the question is less whether the window is open than whether their asset passes the AI "sniff test" and is one the market is actively chasing.

M&A Activity

Selected Recent Healthcare Transactions *($MM)*

Date	Target Name	Acquirer	EV	Enterprise Value / LTM Rev.	Enterprise Value / LTM EBITDA	Description
7/2/2026	Asembia	Peak Rock Capital	NA	NA	NA	Provider of end-to-end technology-enabled commercialization solutions to the specialty pharma industry
7/1/2026	Exdion Healthcare Solutions	Experity (GTCR)	NA	NA	NA	AI-driven SaaS software and services company specializing in the patient chart-to-cash lifecycle
6/29/2026	ClinOhio Research Service	AMR Clinical (Curewell Capital)	NA	NA	NA	Multi-therapeutic research site
6/24/2026	Attune	Chicago Pacific Founders	NA	NA	NA	Agentic engagement platform for healthcare
6/24/2026	Therapy 2000	Avesi Partners	NA	NA	NA	Provider of pediatric therapy services
6/23/2026	Linkwell Health	DUOS	NA	NA	NA	Consumer health engagement company
6/23/2026	Modersys (Applied Materials)(fka SmartFactory Rx)	TELEO Capital Management	NA	NA	NA	Pharmaceutical manufacturing intelligence platform
6/23/2026	West Physics	Incline Equity Partners	NA	NA	NA	Provider of medical and health physics testing and consulting services
6/22/2026	Validic (Kaiser Permanente, Arkin Digital Health)	ChartSpan (BIP Ventures)	NA	NA	NA	Personal health data platform
6/16/2026	Fellow Health Partners	Cleargate Capital Partners	NA	NA	NA	Provider of revenue cycle management services to physician groups, ambulatory surgery centers, and healthcare organizations
6/16/2026	WillowWood (majority stake) (Blue Sea Capital)	CVC Catalyst	NA	NA	NA	Manufacturers of prosthetic products, including prosthetic liners, feet, knees, and other technologies
6/11/2026	Piccolo Medical	Spectrum Vascular (SK Capital)	NA	NA	NA	Developer of catheter guidance products
6/10/2026	CanAide (HCAP Partners)	Med-Metrix (Harvest Partners and A&M Capital Partners)	NA	NA	NA	Provider of Medicaid eligibility and enrollment services and RCM automation solutions
6/10/2026	Gentiva (Humana) minority stake	Undisclosed Investor	$900	NA	NA	Provider of end-of-life services, including hospice and palliative care
6/10/2026	Freedom Senior Services	Gemspring Capital	NA	NA	NA	Provider of home and community-based services focused on providing non-medical personal care for elderly and disabled individuals
6/10/2026	SkillNet	PartsSource (Bain Capital)	NA	NA	NA	Workforce intelligence platform for technology management for hospitals and health systems
6/9/2026	Cooper Strategy	Pillr (Water Street Healthcare Partners)	NA	NA	NA	Helps covered entities capture 340B savings used to fund care for underserved patients
6/9/2026	ECLAT Health Solutions (Gulf Capital)	Management Buyout	NA	NA	NA	Revenue cycle management, risk adjustment and healthcare technology partner
6/9/2026	Jaide Health	AMN Healthcare	NA	NA	NA	Real-time, AI-enabled medical interpretation and translation solution

Sources: Capital IQ, Merger market, and press releases
** Denotes Cain Brothers/KeyBanc Capital Markets participation*
Transaction occurred the past week

Private Placement Activity

Selected Recent Healthcare Transactions *($MM)*

Date	Company	Investor(s)	Type	Amount	Description
6/25/2026	Assort Health	Menlo Ventures (lead)	Series C	$120 $1.2 bn valuation	AI agents platform for the patient journey
6/23/2026	Cadence	Spark Capital (lead), Thrive Capital, General Catalyst, Coatue, B Capital, Corewell Health Ventures, Memorial Hermann, and Duke Health	Series C	$100	Digital health company for patients with chronic conditions
6/22/2026	Ensemble Health Partners	Thoreau Group	Strategic Growth	Undisclosed	Revenue cycle management platform for healthcare companies
6/17/2026	InStride	Echo Health Ventures and FMZ Ventures (co-leads), .406 Ventures, Valtruis, General Catalyst, and Mass General Brigham Ventures	Series C	$30	Insurance-covered specialty program for young people living with complex anxiety, OCD, and related disorders
6/15/2026	Centauri Health (Abry Partners)	Neuberger and Apollo S3 (co-leads)	Continuation Vehicle	$780	Healthcare technology company that delivers data-driven solutions to U.S. health plans
6/8/2026	HST Pathways (Bain Capital and Nexxus Holdings)	Novo Holdings	Strategic	Undisclosed	Cloud-based software platform for ambulatory surgery centers
6/8/2026	Stepful	Oak HC/FT (lead), Foresite Capital, Hearst Ventures, Citi Impact Fund, SemperVirens, Y Combinator, Intermountain Health, and ECMC Education Impact Fund	Series C	$55	AI-powered healthcare workforce training platform
6/3/2026	Collate	Redpoint Ventures (lead), First Round and Conviction Partners	Undisclosed	$95 $1 bn valuation	Platform using AI to automate life sciences paperwork
6/2/2026	Adaptive Innovations	Felicis and Bain Capital Ventures (co-leads), Optum Ventures, Sunflower Capital, Conviction, BoxGroup, SV Angels, Dorm Room Fund, Constellation	Series A	$50	AI native healthcare firm
6/1/2026	42 North	Audax Private Equity and Farallon Capital	Preferred Equity	$80	Dental service organization
5/28/2026	Garner Health	Index Ventures (lead), Kleiner Perkins, Redpoint, Thrive, Sequoia, Founders Fund, and Kaiser Permanente Ventures	Series E	$100 $3 bn valuation	Digital platform provider for patients finding healthcare providers
5/19/2026	Commure	General Catalyst (lead), Sequoia Capital, Morgan Stanley and Kirkland & Ellis	Series C	$70 $7 bn valuation	AI infrastructure platform for health systems
5/19/2026	Nourish	Menlo Ventures (lead), Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures, Y Combinator, BoxGroup, Atomico, Daybreak, and Operator Partners	Series C	$100 $2 bn valuation	Dietitian-led metabolic health clinic
5/19/2026	Vi	General Atlantic, Revelstoke, 1902 Capital and Square Peg (co-leads)	Undisclosed	$145 $2 bn valuation	AI-enabled healthcare technology platform
5/4/2026	Fathom	CVS Health Ventures	Strategic	Undisclosed	Autonomous medical coding
4/30/2026	Iterative Health	Intrepid Growth Partners and GV (co-leads), EDBI, Insight Partners, Obvious Ventures	Series C	$77	Healthcare technology and services company powering clinical research
4/29/2026	Aidoc	Goldman Sachs Alternatives (lead), General Catalyst, SoftBank Investment Advisors, Nventures, Square Peg, TCV, Magma, TLV Partners, Mercy and Hartford HealthCare, Amazon Web Services	Series E	$150	AI-powered clinical solutions platform
4/21/2026	AcuityMD	StepStone Group (lead), Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management	Series C	$80 $1 bn valuation	AI platform for the medical technology industry
4/15/2026	ONTO Health	ARTIS and Humania (co-leads)	Series A	$20	AI-enabled, physician-led fertility and longevity provider
4/7/2026	Route 92 Medical	Sectoral Asset Management and Novo Holdings (co-leads), The Vertical Group, USVP Management, Norwest and InnovaHealth Partners	Undisclosed	$50	Medical devices for neurovascular intervention, focusing on catheter systems for the treatment of acute ischemic stroke
3/26/2026	eMed	AON Consulting (lead)	Undisclosed	$200 $2 bn valuation	Clinically managed GLP-1 programs for employers

Sources: Capital IQ, Merger market, and press releases
** Denotes Cain Brothers/KeyBanc Capital Markets participation*
Transaction occurred over the past week

Equity Capital Markets

Market Overview

- ECM issuance continues to remain strong across products following the blockbuster SpaceX pricing.
  - Last week: 3 IPOs; 9 follow-ons; 4 converts
- IPO market remains open for business, with 3 IPOs pricing in the past week for total proceeds of ~$2.2 BN.
- Follow-on issuance was subdued in the latter half of last week due to the Friday market holiday and Q2 earnings blackouts.
- Investors and issuers will continue to look toward the upcoming earnings season and economic data releases to fuel issuance.

U.S. ECM Offerings *(LTM; IPOs, Follow-ons & Converts)*



ECM Activity *(Last 4 Weeks & YoY)*

	2026 - Last 4 Weeks			2025 - Last 4 Weeks		
	Vol ($MM)	# Deals	% Share	Vol ($MM)	# Deals	% Share
IPO	90,745	11	77%	3,044	9	8%
CONV	14,936	18	13%	16,747	16	46%
FO	12,108	28	10%	16,789	37	46%
Total	**117,789**	**57**	**100%**	**36,580**	**62**	**100%**

	2026 YTD			2025 YTD		
	Vol ($MM)	# Deals	% Share	Vol ($MM)	# Deals	% Share
IPO	126,178	58	40%	14,172	29	11%
CONV	82,342	76	26%	42,945	47	34%
FO	109,393	205	34%	71,008	126	55%
Total	**317,913**	**339**	**100%**	**128,125**	**202**	**100%**

IPO & Follow-on 1-Week Performance *(LTM)*



Most Recent Healthcare Initial Public Offerings *($MM)*

Issuer Information				Deal Sizing				Pricing		Performance	
Pricing Date	Company	Sector	Ticker	Deal Value ($MM)	Market Cap ($MM)	Deal as % of Mkt. Cap	% Primary	Offer Price	Final Range	1-Day	1-Week
5/12/2026	GMR Solutions	Healthcare Services	GMRS	$478.7	$3,347.2	14.3%	100.0%	$15.00	$22.00 - $25.00	(6.8%)	(19.5%)
5/7/2026	Mobia Medical	Medical Products	MOBI	$150.0	$496.3	30.2%	100.0%	$15.00	$14.00 - $16.00	(21.7%)	(19.7%)
4/16/2026	Alamar Biosciences	Diagnostics	ALMR	$219.9	$1,130.9	19.4%	100.0%	$17.00	$15.00 - $17.00	29.4%	42.8%
3/5/2026	MiniMed Group	Medical Products	MMED	$560.0	$5,616.3	10.0%	100.0%	$20.00	$26.00 - $30.00	(7.6%)	(17.4%)
12/16/2025	Medline	Medical Products	MDLN	$7,204.7	$38,097.8	18.9%	72.1%	$29.00	$26.00 - $30.00	41.4%	50.5%

Most Recent Healthcare Follow-on Offerings *($MM)*

Issuer Information					Deal Sizing				Pricing	Performance	
Pricing Date	Company	Sector	Deal Type	Ticker	Deal Value ($MM)	Market Cap ($MM)	Deal as % of Mkt. Cap	% Primary	Discount to File	1-Day	1-Week
6/16/2026	Sophia Genetics	Diagnositcs	Marketed	SOPH	$57.5	$405.8	14.2%	100.0%	(3.7%)	10.3%	10.1%
6/5/2026	Nyxoah	Medical Products	Marketed	NYXH	$95.0	$287.8	33.0%	100.0%	(40.3%)	(19.2%)	(19.2%)
5/21/2026	Medline	Medical Products	Marketed	MDLN	$2,684.5	$48,737.8	5.5%	0.0%	(1.9%)	0.0%	(0.5%)
5/11/2026	Sotera Health Group	Medical Products	Bought	SHC	$486.2	$4,400.1	11.0%	0.0%	(1.0%)	2.4%	(0.5%)
5/7/2026	LifeStance Health Group	Healthcare Services	Bought	LFST	$236.4	$3,432.3	6.9%	0.0%	(7.9%)	(5.5%)	(0.5%)

Most Recent Healthcare Convertible Debt Offerings *($MM)*

Issuer Information				Deal Sizing			Pricing	
Pricing Date	Company	Sector	Ticker	Deal Value ($MM)	Market Cap ($MM)	Deal as % of Mkt. Cap	Coupon	Premium
6/17/2026	Adaptive Biotechnologies	Diagnostics	ADPT	$345.0	$2,756.0	12.5%	0.00%	40.00%
6/17/2026	NeoGenomics	Healthcare Services	NEO	$316.3	$1,365.9	3.2%	0.75%	35.00%
2/24/2026	Tandem Diabetes Care	Healthcare Products	TNDM	$300.0	$1,838.0	16.3%	0.00%	37.50%
11/4/2025	Guardant Health	Diagnostics	GH	$402.5	$12,745.9	3.2%	0.00%	35.00%
9/16/2025	Oscar Health	Health Insurance	OSCR	$410.0	$4,842.8	8.5%	2.25%	32.50%

Sources: Bloomberg, Capital IQ, Dealogic, and Press Releases

*Note: Transactions include IPOs, follow-ons (including bought deals) and convertible offerings of $25MM or more priced on a U.S.-based exchange; Price performance includes both marketed and bought deal follow-ons; * denotes Cain Brothers / KBCM transaction; excludes SPACs and fixed price IPOs*

Transaction occurred the past week

Public Equity Indices

Equity Indices (as of July 3, 2026)

Index	Wk Open	Wk Close	Returns 52 Week	Returns Weekly
DJIA	51,876	52,900	18.0%	2.0%
S&P 500	7,354	7,483	19.2%	1.8%
NASDAQ	25,298	25,833	25.4%	2.1%
Russell 2000	3,010	2,996	33.2%	(0.5%)
NYSE Healthcare	28,274	28,692	20.2%	1.5%

Cain Brothers Indicies	Returns 52 Week	Returns Weekly
Acute Care	(0.1%)	5.6%
Alternate Site Services	(0.9%)	5.8%
Diagnostics	6.7%	4.5%
Distribution	10.2%	2.4%
Healthcare IT	(18.7%)	8.1%
Healthcare REITs	59.3%	3.5%
Managed Care	29.2%	1.2%
Medical Technology	(4.8%)	2.6%
Outsourced Services	50.8%	5.7%
Pharma Services	16.2%	6.5%
Pharmacy	51.6%	0.4%
Primary Care	81.9%	3.9%
Post-Acute Care Services	34.8%	3.7%
Post-Acute Care Facilities	35.5%	3.6%

Cain Brothers Healthcare Indices (1YR Performance)



Sources: Cain Brothers, Bloomberg, Capital IQ

High Grade, High Yield & Leveraged Loan Market

Market Summary

High Grade

- The IG primary market remained active heading into the holiday weekend, as 10 issuers priced $18.2 BN in volume in just two days.

High Yield

- As tech-driven volatility rippled through across financial markets, high yield primary market activity remained steadfast, with more than $7.0 BN of bond volume marking a three-week high.

Term Loan B Market

- CLO issuance has slowed significantly amidst the volatile backdrop after a strong start to the year.

HY Index Yield & Spread (YTD)



Weekly New Issue Volume *($BN)*



New-Issue Clearing Yields[1] *($MM)*

Double-B Issuers	1Q26	2Q26	30-Day Rolling Average 07/03/26
Ba1	S+210 / 6.2%	S+214 / 5.8%	S+245 / 6.1%
Ba2	S+239 / 6.5%	S+190 / 5.6%	S+178 / 5.7%
Ba3	S+220 / 6.2%	S+238 / 6.1%	S+223 / 5.9%
Single-B Issuers	**1Q26**	**2Q26**	**30-Day Rolling Average 07/03/26**
B1	S+284 / 6.6%	S+251 / 6.2%	S+245 / 6.1%
B2	S+322 / 7.0%	S+325 / 7.0%	S+178 / 5.7%
B3	S+351 / 7.3%	S+404 / 7.9%	S+223 / 5.9%

Most Recent Healthcare High-Grade Issuances *($MM)*

Date	Issuer	Security	Size	Ratings	Coupon	Maturity	Spread	IPT-Pricing
6/22/2026	Agilent Technologies Inc	Sr Notes	$600	Baa1/BBB+/BBB+	4.900%	1/15/2032	+62	28 bps
5/18/2026	Merck	Sr Notes	$1,000	Aa3/A+/--	4.300%	5/22/2028	+25	25 bps
5/18/2026	Merck	Sr Notes	$500	Aa3/A+/--	3.935%	5/22/2028	SOFR+37	25 bps

Most Recent Healthcare High-Yield Issuances *($MM)*

Date	Issuer	Security	Size	Ratings	Coupon	Maturity	Spread	Price Talk
6/30/2026	Prestige Brands	Sr. Notes	$400	B1/BB-/NR	6.250%	7/15/2034	190 bps	6.375% area
6/17/2026	Gentiva	Sr. Sec. Notes	$500	B3/B-/NR	8.000%	6/30/2031	382 bps	8.125%-8.375%

Most Recent Healthcare Leveraged Loan Issuances *($MM)*

Date	Issuer	Ownership	Corp. Ratings	Use of Proceeds	Size	Pricing	Yield
3/19/2026	Select Medical Corporation	WCAS	B1 / B+	LBO	$100	SOFR+300, 0% @ 99	6.925%
2/5/2026	Resonetics LLC	Carlyle Group	B3 / B-	Acquisition	$220	SOFR+275, 0.75% @ 99.25	6.606%
1/29/2026	TEAM Services Group	General Atlantic	B2 / B-	LBO	$700	SOFR+525, 0% @ 99	9.171%
1/29/2026	Dechra Pharmaceuticals	EQT Partners	B2 / B-	Repricing	$834	SOFR+275, 0% @ 100	6.421%

Most Recent Healthcare Pro Rata Issuances *($MM)*

Date	Issuer	Ownership	Ratings	Use of Proceeds	Size	Pricing (in bps)	Financial Covenants
5/15/2026	VSP Optical Group, Inc.*	Private	Baa2 / NR	Refinancing	$1,500mm 5-year Revolver $1,375mm 5-year Term Loan A	Ratings-based Grid SOFR+87.5-150 Opens at SOFR+100	Max. Net Leverage Ratio: 3.75x w/ step-up to 4.25x Min. Interest Coverage Ratio: 2.50x
2/12/2026	Alkermes	Public	Ba2 / BB	Acquisition	$750mm 5-year Term Loan A	Leverage-based Grid SOFR+250-300 Opens at SOFR+275	Max. Secured Net Leverage Ratio: 4.25x Min. Interest Coverage Ratio: 2.50x

Sources: Capital IQ, Mergermarket, and press releases
** Denotes Cain Brothers/KeyBanc Capital Markets participation*
Transaction occurred over the past week

Public Finance Market

Market Overview

- The yield on the benchmark 10-year U.S. Treasury Note increased 9 bps week-over-week, closing at 4.49% on Friday. 10-year MMD decreased 1 bp week-over-week.
- Healthcare Public Issuance in 2025 increased 34% vs 2024. YTD 2026 Issuance through June 26th was 24% higher than YTD 2025 through the end of June.
- Muni bond funds gained $1.7 BN and high yield funds gained $535 MM for the week ended July 1st.

MMD & UST Yield Curve



Weekly New Issue Volume *($MM)*



Benchmark Yields

Treasury Yields			MMD Yields			Ratio
Yr	Yield	Δ (W/W)	Yr	Yield	Δ (W/W)	MMD/ UST
2	4.14%	5 bps	2	2.35%	(3 bps)	57%
10	4.49%	9 bps	10	2.96%	(1 bps)	66%
30	4.98%	12 bps	30	4.20%	(3 bps)	84%

Healthcare Public Issuance Overview



Recent Healthcare Public Issuance

Healthcare Public Issuance										
Borrower/Enhancement	Par (000s)	State	Issuer	Tax Status	LT Ratings (M/S/F)	Final Mat.	Call, Put or Reprice*	Final Mat. Cpn.	YTW	YTM
Recent Pricings, Week of 6/29										
Memorial Hermann Health System	100,000	CO	HCTCEF	TE	NR / AA- / NR	2056	2026(C)	2.15%	2.15%	N/A
Exp. Pricings, Week of 7/6										
McCamey County Hospital District	14,400	TX	MCHD	TE	Ba2 / NR / NR	-	-	-	-	-

Sources: Bloomberg, TM3
** Denotes Cain Brothers/KeyBanc Capital Markets participation*
NC = No Call, MWC = Make Whole Call, (C) = Par Call, (P) = 1st Put, (R) = Reprice Date

Relevant News

[What Revenue Cycle Leaders Need To Know About The IDR Final Rule]

HealthLeaders Media | June 23, 2026

The Federal IDR Operations final rule introduces vital changes to fees, batching, and eligibility, but a lack of federal enforcement leaves providers battling payers for post-decision payments.

US Health Spending Spikes To $5.7T In 2025, Though Growth Should Moderate, CMS Finds

Healthcare Dive | June 24, 2026

Utilization — not cost growth — continues to accelerate spending, government actuaries said. Rising prescription drug spending, including on GLP-1s, is especially acute. U.S. healthcare spending spiked 7.3% last year to reach $5.7 trillion, driven by soaring spending on hospital services and pricey prescription drugs like GLP-1s, according to new government data

Patient Messages To Providers Have Skyrocketed, Study Finds

Healthcare Dive | June 25, 2026

Patients' access to their health information online — and the ability to engage with their clinicians — through portals has expanded significantly over the past decade. That could have benefits for patients. Research shows the use of portals is linked to improved patient satisfaction, as well as better medication adherence, self-management of disease and preventative care.

Millions Of Americans Drop Obamacare Plans After Withdrawal Of Subsidies

Wall Street Journal | June 26, 2026

Nearly four million people who signed up for Affordable Care Act plans this year have already dropped their coverage after the loss of subsidies resulted in sharply higher costs. The Department of Health and Human Services released figures Friday that offered the first definitive view of enrollment after the withdrawal of enhanced government support for ACA plans, which ended at the start of this year.

Clinicians' Compensation Rose 4.3% Across 2025: AMGA

Fierce Healthcare | June 26, 2026

Clinical care providers' total compensation rose a median 4.3% across 2025, a slight pullback from the two years prior but overall a continuation of the "steady climb" fueled by heightened demand for care and talent, hundreds of medical groups and health systems reported in a recent annual survey.

Nursing Homes Brace For Staff Shortages After Supreme Court Ruling

Becker's Hospital Review | June 29, 2026

The Supreme Court's June 25 decision to pause lower-court rulings blocking the end of Temporary Protected Status for Haitian and Syrian refugees could create significant workforce disruption for skilled nursing and long-term care providers.

Disclaimer

Industry Insights is compiled weekly by Cain Brothers, a division of KeyBanc Capital Markets, 1301 Avenue of the Americas, 37th Floor, New York, NY 10019; Ph: (212) 869-5600. To receive our Industry Insights email, please subscribe at key.com/newsletters. For questions regarding Industry Insights, please email rgruber@cainbrothers.com.

"Cain Brothers, a division of KeyBanc Capital Markets" is a trade name of KeyBanc Capital Markets Inc., Member FINRA/SIPC. KeyBanc Capital Markets Inc. and KeyBank National Association ("KeyBank N.A.") are separate, but affiliated companies. Securities products and services are offered by KeyBanc Capital Markets Inc. and its licensed securities representatives. Banking products and services are offered by KeyBank N.A.

This report was not issued by our research department. The information contained in this report has been obtained from sources deemed to be reliable but is not represented to be complete, and it should not be relied upon as such. This report does not purport to be a complete analysis of any security, issuer, or industry and is not an offer or a solicitation of an offer to buy or sell any securities. This report is prepared for general information purposes only.

Please read our complete KeyBanc Capital Markets disclosure statement.

CAIN BROTHERS
A division of
KeyBanc Capital Markets

July 15, 2026

Industry Insights

Healthcare Market Report



Banker Commentary:

Ambient AI and the Shift from Documentation to Clinical Intelligence

Contents

Ambient AI and the Shift from Documentation to Clinical Intelligence

Banker Commentary by Adam Johnston

Two recent developments have reshaped the competitive landscape in ambient AI. Epic has expanded native AI charting capabilities within the clinical workflow, while Doximity has made AI-powered note generation broadly available at no cost. Together, these moves have increased pricing pressure across the sector and raised the bar for differentiation.

The result is a market where documentation is becoming increasingly difficult to position as a standalone product category. As ambient capabilities become more deeply embedded within existing clinical systems and more widely available to providers, the focus of competition is shifting toward workflows that can be built on top of encounter data.

Many of the leading vendors have already moved beyond note generation into coding, prior authorization, clinical decision support, and revenue cycle workflows. Health systems are increasingly evaluating these platforms, not only on documentation quality, but on their ability to improve productivity, reduce administrative burden, and enhance financial performance.

For investors, the more important question is where value accrues as ambient documentation becomes a standard part of the clinical workflow. Early evidence suggests that the largest opportunities may reside with platforms capable of converting conversational data into actionable clinical, operational, and financial intelligence.

Market Overview

Ambient AI has evolved rapidly from a point solution designed to reduce documentation burden into a broader layer of healthcare workflow infrastructure. Initially adopted as a way to address physician burnout and after-hours charting, the technology is increasingly being applied to processes that influence care delivery, coding accuracy, reimbursement, and administrative efficiency.

Adoption has accelerated across large health systems, moving from limited pilots to enterprise-wide deployments. The underlying drivers remain unchanged: persistent physician staffing challenges, growing documentation requirements, and ongoing pressure to improve clinical productivity. As one of the first healthcare applications of generative AI to achieve meaningful scale, ambient scribing attracted significant investment and became an early proving ground for AI-enabled workflow automation.

The vendor landscape expanded quickly alongside demand. Early leaders, such as Nuance DAX Copilot and Abridge, established positions through enterprise-grade performance and integration capabilities. A broader group of competitors, including Ambience, Suki, Nabla, DeepScribe, Freed, and more recently, DeepCura, sought differentiation through workflow design, specialty coverage, implementation speed, and usability.

As the market has matured, however, it has become increasingly clear that incremental improvements in documentation quality alone are unlikely to support durable competitive advantages. The emergence of free offerings and EHR embedded solutions has reinforced this dynamic.

continued…

Doximity's decision to provide AI documentation capabilities at no cost has placed pressure on the lower end of the market, while Epic's native solution has prompted many health systems to reassess the need for separate ambient documentation vendors. Given Epic's entrenched position across U.S. hospitals, embedded functionality carries a significant distribution advantage.

This shift has implications for purchasing behavior. Buyers are increasingly evaluating ambient platforms through the lens of broader workflow impact rather than note generation alone. The discussion is moving toward administrative efficiency, coding performance, reimbursement outcomes, and integration with payer processes.

The Rise and Limits of Ambient Documentation

Ambient documentation gained traction because it addressed a well understood and highly visible challenge. By automatically capturing and summarizing patient physician conversations, these tools reduced time spent charting and improved clinician satisfaction.

That value proposition remains important. For many organizations, documentation automation continues to deliver meaningful productivity benefits and represents one of the most tangible applications of AI in clinical settings.

At the same time, the strategic value of ambient AI has always extended beyond the note itself. The more significant opportunity lies in transforming previously unstructured conversations into structured data that can support additional workflows.

Once encounter data becomes machine readable, a much wider range of use cases becomes possible. Coding, prior authorization, clinical decision support, order management, patient follow up, and revenue cycle workflows can all be informed directly by information captured during the clinical encounter.

This transition is now well underway across the industry. Documentation is increasingly serving as the foundational data layer for a broader set of clinical, administrative, and financial workflows, extending the role of ambient AI well beyond note generation.

Scaling the Clinical Intelligence Layer

Epic's entry into ambient AI has helped clarify the competitive environment for independent vendors. By delivering a native solution within the EHR, Epic has established a baseline level of functionality that is likely sufficient for many organizations. As a result, differentiation is increasingly occurring beyond documentation.

Most vendors now offer some combination of coding support, authorization workflows, and clinical decision assistance. The more meaningful distinction lies in workflow depth, integration quality, and the ability to generate measurable operational outcomes.

Abridge provides one example of this evolution. Through its partnership with Availity, the company has integrated payer requirements directly into the clinical workflow, allowing authorization-related processes to begin during the patient encounter rather than after it. This approach extends the platform's role beyond documentation and places it closer to the flow of clinical and financial transactions.

Suki has pursued a different strategy, placing greater emphasis on coding and revenue cycle integration. By leveraging encounter data to automate coding workflows and integrating with major healthcare platforms, Suki is positioning itself as an intelligence layer embedded within existing infrastructure rather than a standalone application.

DeepCura represents a more vertically integrated model. Its architecture spans chart review, documentation, coding, order management, and follow-up activities, reflecting an effort to manage a larger portion of the encounter workflow within a single system.

Internationally, Heidi Health has expanded along similar lines. The introduction of Heidi Evidence and the acquisition of AutoMedica broadened the company's capabilities into clinical reasoning and decision support, extending its role beyond documentation and into care delivery workflows.

Across these approaches, a common pattern is emerging. While differences in documentation quality remain, competitive dispersion increasingly reflects workflow breadth, integration depth, and the ability to influence downstream clinical and administrative processes.

Conclusion: The Platform Consolidation Thesis

The ambient AI market is beginning to separate into two distinct layers. At the foundation sits documentation, an increasingly standardized capability shaped by EHR integration, broader distribution, and growing pricing pressure. Documentation remains an important feature, but market dynamics suggest that it is becoming less likely to sustain meaningful differentiation on its own.

Higher in the stack sits the area where clinical intelligence, workflow automation, reimbursement optimization, and payer-provider connectivity converge. This is where much of the industry's current innovation is taking place and where long-term value creation is increasingly concentrated. The strongest platforms are likely to be those that can translate ambient data into measurable operational outcomes across multiple domains. Documentation, coding, authorization, clinical reasoning, and revenue cycle execution are becoming more interconnected, creating opportunities for vendors that can operate across the full workflow rather than a single step within it.

As the market continues to mature, competitive outcomes will depend less on the quality of the note and more on the ability to influence what happens after the encounter. The companies that emerge as long-term winners are likely to be those that establish themselves at the center of these downstream workflows, where clinical decisions, administrative processes, and reimbursement outcomes converge.

M&A Activity

Selected Recent Healthcare Transactions *($MM)*

Date	Target Name	Acquirer	EV	Enterprise Value / LTM Rev.	Enterprise Value / LTM EBITDA	Description
7/9/2026	Canadian Dental Labs	CenterGate Capital	NA	NA	NA	Manufacturer of dental prosthetics and orthodontic appliances
7/9/2026	Empower Emergency Physicians	Emergency Care Partners (Varsity Healthcare Partners, Regal Healthcare Capital Partners)	NA	NA	NA	Independent emergency medicine group
7/7/2026	Corza Medical's Biosurgery Business Unit (GTCR)	EQT	NA	NA	NA	Biologic and surgical products
7/7/2026	MatrixCare (Resmed)	Frazier Healthcare Partners	NA	NA	NA	Provider of cloud-based EHR software purpose-built for out-of-hospital care settings
7/7/2026	The School of EMS	Grant Avenue Capital	NA	NA	NA	Education and training to emergency medical services professionals
7/2/2026	Asembia	Peak Rock Capital	NA	NA	NA	Provider of end-to-end technology-enabled commercialization solutions to the specialty pharma industry
7/1/2026	Exdion Healthcare Solutions	Experity (GTCR)	NA	NA	NA	AI-driven SaaS software and services company specializing in the patient chart-to-cash lifecycle
6/29/2026	ClinOhio Research Service	AMR Clinical (Curewell Capital)	NA	NA	NA	Multi-therapeutic research site
6/24/2026	Attune	Chicago Pacific Founders	NA	NA	NA	Agentic engagement platform for healthcare
6/24/2026	Therapy 2000	Avesi Partners	NA	NA	NA	Provider of pediatric therapy services
6/23/2026	Linkwell Health	DUOS	NA	NA	NA	Consumer health engagement company
6/23/2026	Modersys (Applied Materials)(fka SmartFactory Rx)	TELEO Capital Management	NA	NA	NA	Pharmaceutical manufacturing intelligence platform
6/23/2026	West Physics	Incline Equity Partners	NA	NA	NA	Provider of medical and health physics testing and consulting services
6/22/2026	Validic (Kaiser Permanente, Arkin Digital Health)	ChartSpan (BIP Ventures)	NA	NA	NA	Personal health data platform
6/16/2026	Fellow Health Partners	Cleargate Capital Partners	NA	NA	NA	Provider of revenue cycle management services to physician groups, ambulatory surgery centers, and healthcare organizations
6/16/2026	WillowWood (majority stake) (Blue Sea Capital)	CVC Catalyst	NA	NA	NA	Manufacturers of prosthetic products, including prosthetic liners, feet, knees, and other technologies
6/11/2026	Piccolo Medical	Spectrum Vascular (SK Capital)	NA	NA	NA	Developer of catheter guidance products
6/10/2026	CanAide (HCAP Partners)	Med-Metrix (Harvest Partners and A&M Capital Partners)	NA	NA	NA	Provider of Medicaid eligibility and enrollment services and RCM automation solutions
6/10/2026	Gentiva (Humana) minority stake	Undisclosed Investor	$900	NA	NA	Provider of end-of-life services, including hospice and palliative care

Sources: Capital IQ, Merger market, and press releases
** Denotes Cain Brothers/KeyBanc Capital Markets participation*
Transaction occurred the past week

Private Placement Activity

Selected Recent Healthcare Transactions *($MM)*

Date	Company	Investor(s)	Type	Amount	Description
7/8/2026	Pearl Health	Andreessen Horowitz (equity lead), Viking Global Investors, AlleyCorp, Ulysses Capital, Trinity Capital (debt)	Equity and Debt	$110	AI-powered predictive insights and financial modeling platform for primary care providers
7/7/2026	Pediatrica Health Group	Valspring Capital (lead), M33 Growth	Series B	$28	multi-site pediatric primary care organization dedicated to delivering Next Generation CareSM to families
6/25/2026	Assort Health	Menlo Ventures (lead)	Series C	$120 $1.2 bn valuation	AI agents platform for the patient journey
6/23/2026	Cadence	Spark Capital (lead), Thrive Capital, General Catalyst, Coatue, B Capital, Corewell Health Ventures, Memorial Hermann, and Duke Health	Series C	$100	Digital health company for patients with chronic conditions
6/22/2026	Ensemble Health Partners	Thoreau Group	Strategic Growth	Undisclosed	Revenue cycle management platform for healthcare companies
6/17/2026	InStride	Echo Health Ventures and FMZ Ventures (co-leads), .406 Ventures, Valtruis, General Catalyst, and Mass General Brigham Ventures	Series C	$30	Insurance-covered specialty program for young people living with complex anxiety, OCD, and related disorders
6/15/2026	Centauri Health (Abry Partners)	Neuberger and Apollo S3 (co-leads)	Continuation Vehicle	$780	Healthcare technology company that delivers data-driven solutions to U.S. health plans
6/8/2026	HST Pathways (Bain Capital and Nexxus Holdings)	Novo Holdings	Strategic	Undisclosed	Cloud-based software platform for ambulatory surgery centers
6/8/2026	Stepful	Oak HC/FT (lead), Foresite Capital, Hearst Ventures, Citi Impact Fund, SemperVirens, Y Combinator, Intermountain Health, and ECMC Education Impact Fund	Series C	$55	AI-powered healthcare workforce training platform
6/3/2026	Collate	Redpoint Ventures (lead), First Round and Conviction Partners	Undisclosed	$95 $1 bn valuation	Platform using AI to automate life sciences paperwork
6/2/2026	Adaptive Innovations	Felicis and Bain Capital Ventures (co-leads), Optum Ventures, Sunflower Capital, Conviction, BoxGroup, SV Angels, Dorm Room Fund, Constellation	Series A	$50	AI native healthcare firm
6/1/2026	42 North	Audax Private Equity and Farallon Capital	Preferred Equity	$80	Dental service organization
5/28/2026	Garner Health	Index Ventures (lead), Kleiner Perkins, Redpoint, Thrive, Sequoia, Founders Fund, and Kaiser Permanente Ventures	Series E	$100 $3 bn valuation	Digital platform provider for patients finding healthcare providers
5/19/2026	Commure	General Catalyst (lead), Sequoia Capital, Morgan Stanley and Kirkland & Ellis	Series C	$70 $7 bn valuation	AI infrastructure platform for health systems
5/19/2026	Nourish	Menlo Ventures (lead), Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures, Y Combinator, BoxGroup, Atomico, Daybreak, and Operator Partners	Series C	$100 $2 bn valuation	Dietitian-led metabolic health clinic
5/19/2026	Vi	General Atlantic, Revelstoke, 1902 Capital and Square Peg (co-leads)	Undisclosed	$145 $2 bn valuation	AI-enabled healthcare technology platform
5/4/2026	Fathom	CVS Health Ventures	Strategic	Undisclosed	Autonomous medical coding
4/30/2026	Iterative Health	Intrepid Growth Partners and GV (co-leads), EDBI, Insight Partners, Obvious Ventures	Series C	$77	Healthcare technology and services company powering clinical research
4/29/2026	Aidoc	Goldman Sachs Alternatives (lead), General Catalyst, SoftBank Investment Advisors, Nventures, Square Peg, TCV, Magma, TLV Partners, Mercy and Hartford HealthCare, Amazon Web Services	Series E	$150	AI-powered clinical solutions platform
4/21/2026	AcuityMD	StepStone Group (lead), Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management	Series C	$80 $1 bn valuation	AI platform for the medical technology industry
4/15/2026	ONTO Health	ARTIS and Humania (co-leads)	Series A	$20	AI-enabled, physician-led fertility and longevity provider

Sources: Capital IQ, Merger market, and press releases
** Denotes Cain Brothers/KeyBanc Capital Markets participation*
Transaction occurred over the past week

Equity Capital Markets

Market Overview

- ECM issuance continues to remain strong across products powering through re-heightened geopolitical tensions in the Middle East
  - Last week: 2 IPOs; 9 follow-ons; 4 converts
- The IPO market remains active with multiple IPOs on the road this week with many more on public file as they look to price ahead of the upcoming financial staleness deadline on August 14th requiring the inclusion of Q2 financials within their registration statements
- Follow-on issuance has remained steady as issuers and sponsors alike navigate through earnings-related blackout periods as earnings season kicks off

U.S. ECM Offerings *(LTM; IPOs, Follow-ons & Converts)*



ECM Activity *(Last 4 Weeks & YoY)*

	2026 - Last 4 Weeks			2025 - Last 4 Weeks		
	Vol ($MM)	# Deals	% Share	Vol ($MM)	# Deals	% Share
IPO	1,102	5	6%	1,238	4	8%
CONV	6,560	13	37%	5,991	6	39%
FO	10,172	20	57%	8,110	25	53%
Total	17,834	38	100%	15,339	35	100%

	2026 YTD			2025 YTD		
	Vol ($MM)	# Deals	% Share	Vol ($MM)	# Deals	% Share
IPO	124,536	57	39%	14,172	29	11%
CONV	82,903	77	26%	42,945	47	33%
FO	111,104	207	35%	71,750	130	56%
Total	318,543	341	100%	128,867	206	100%

IPO & Follow-on 1-Week Performance *(LTM)*



Most Recent Healthcare Initial Public Offerings *($MM)*

Issuer Information				Deal Sizing				Pricing		Performance	
Pricing Date	Company	Sector	Ticker	Deal Value ($MM)	Market Cap ($MM)	Deal as % of Mkt. Cap	% Primary	Offer Price	Final Range	1-Day	1-Week
5/12/2026	GMR Solutions	Healthcare Services	GMRS	$478.7	$3,347.2	14.3%	100.0%	$15.00	$22.00 - $25.00	(6.8%)	(19.5%)
5/7/2026	Mobia Medical	Medical Products	MOBI	$150.0	$496.3	30.2%	100.0%	$15.00	$14.00 - $16.00	(21.7%)	(19.7%)
4/16/2026	Alamar Biosciences	Diagnostics	ALMR	$219.9	$1,130.9	19.4%	100.0%	$17.00	$15.00 - $17.00	29.4%	42.8%
3/5/2026	MiniMed Group	Medical Products	MMED	$560.0	$5,616.3	10.0%	100.0%	$20.00	$26.00 - $30.00	(7.6%)	(17.4%)
12/16/2025	Medline	Medical Products	MDLN	$7,204.7	$38,097.8	18.9%	72.1%	$29.00	$26.00 - $30.00	41.4%	50.5%

Most Recent Healthcare Follow-on Offerings *($MM)*

Issuer Information					Deal Sizing				Pricing	Performance	
Pricing Date	Company	Sector	Deal Type	Ticker	Deal Value ($MM)	Market Cap ($MM)	Deal as % of Mkt. Cap	% Primary	Discount to File	1-Day	1-Week
6/16/2026	Sophia Genetics	Diagnositcs	Marketed	SOPH	$57.5	$405.8	14.2%	100.0%	(3.7%)	10.3%	10.1%
6/5/2026	Nyxoah	Medical Products	Marketed	NYXH	$95.0	$287.8	33.0%	100.0%	(40.3%)	(19.2%)	(19.2%)
5/21/2026	Medline	Medical Products	Marketed	MDLN	$2,684.5	$48,737.8	5.5%	0.0%	(1.9%)	0.0%	(0.5%)
5/11/2026	Sotera Health Group	Medical Products	Bought	SHC	$486.2	$4,400.1	11.0%	0.0%	(1.0%)	2.4%	(0.5%)
5/7/2026	LifeStance Health Group	Healthcare Services	Bought	LFST	$236.4	$3,432.3	6.9%	0.0%	(7.9%)	(5.5%)	(0.5%)

Most Recent Healthcare Convertible Debt Offerings *($MM)*

Issuer Information				Deal Sizing			Pricing	
Pricing Date	Company	Sector	Ticker	Deal Value ($MM)	Market Cap ($MM)	Deal as % of Mkt. Cap	Coupon	Premium
6/17/2026	Adaptive Biotechnologies	Diagnostics	ADPT	$345.0	$2,756.0	12.5%	0.00%	40.00%
6/17/2026	NeoGenomics	Healthcare Services	NEO	$316.3	$1,365.9	3.2%	0.75%	35.00%
2/24/2026	Tandem Diabetes Care	Healthcare Products	TNDM	$300.0	$1,838.0	16.3%	0.00%	37.50%
11/4/2025	Guardant Health	Diagnostics	GH	$402.5	$12,745.9	3.2%	0.00%	35.00%
9/16/2025	Oscar Health	Health Insurance	OSCR	$410.0	$4,842.8	8.5%	2.25%	32.50%

Sources: Bloomberg, Capital IQ, Dealogic, and Press Releases

*Note: Transactions include IPOs, follow-ons (including bought deals) and convertible offerings of $25MM or more priced on a U.S.-based exchange; Price performance includes both marketed and bought deal follow-ons; * denotes Cain Brothers / KBCM transaction; excludes SPACs and fixed price IPOs*

Transaction occurred the past week

Public Equity Indices

Equity Indices (as of July 10, 2026)

Index	Wk Open	Wk Close	Returns 52 Week	Returns Weekly
DJIA	52,900	52,637	17.9%	(0.5%)
S&P 500	7,483	7,575	20.6%	1.2%
NASDAQ	25,833	26,282	27.4%	1.7%
Russell 2000	2,996	2,978	31.6%	(0.6%)
NYSE Healthcare	28,280	28,144	17.2%	(0.5%)

Cain Brothers Indicies	Returns 52 Week	Returns Weekly
Acute Care	(1.5%)	(0.9%)
Alternate Site Services	(1.4%)	(0.3%)
Diagnostics	3.9%	(2.9%)
Distribution	12.2%	1.2%
Healthcare IT	(19.9%)	(1.3%)
Healthcare REITs	56.1%	(1.9%)
Managed Care	32.5%	(0.2%)
Medical Technology	(5.9%)	(0.8%)
Outsourced Services	51.1%	(3.8%)
Pharma Services	14.9%	0.1%
Pharmacy	54.9%	(0.6%)
Primary Care	80.2%	(1.2%)
Post-Acute Care Services	41.8%	3.0%
Post-Acute Care Facilities	40.2%	1.2%

Cain Brothers Healthcare Indices (1YR Performance)



Sources: Cain Brothers, Bloomberg, Capital IQ

High Grade, High Yield & Leveraged Loan Market

Market Summary

High Grade

- The IG primary market landed firmly ahead of expectations as 20 issuers tapped the market for $53.5 BN in volume.

High Yield

- The high yield primary market remained sluggish following the holiday-shortened week, as a limited issuance pipeline and heightened rate volatility kept activity muted, with only two issuers accessing the market for $800 MM of volume.

Term Loan B Market

- CLO issuance has slowed significantly amidst the volatile backdrop after a strong start to the year.

HY Index Yield & Spread (YTD)



Weekly New Issue Volume ($BN)



New-Issue Clearing Yields[1] ($MM)

Double-B Issuers	1Q26	2Q26	30-Day Rolling Average 07/10/26
Ba1	S+210 / 6.2%	S+214 / 5.8%	S+269 / 6.4%
Ba2	S+239 / 6.5%	S+190 / 5.6%	S+172 / 5.7%
Ba3	S+220 / 6.2%	S+238 / 6.1%	S+223 / 5.9%
Single-B Issuers	**1Q26**	**2Q26**	**30-Day Rolling Average 07/10/26**
B1	S+284 / 6.6%	S+251 / 6.2%	S+279 / 6.5%
B2	S+322 / 7.0%	S+325 / 7.0%	S+351 / 7.4%
B3	S+351 / 7.3%	S+404 / 7.9%	S+396 / 7.9%

Most Recent Healthcare High-Grade Issuances ($MM)

Date	Issuer	Security	Size	Ratings	Coupon	Maturity	Spread	IPT-Pricing
6/22/2026	Agilent Technologies Inc	Sr Notes	$600	Baa1/BBB+/BBB+	4.900%	1/15/2032	+62	28 bps
5/18/2026	Merck	Sr Notes	$1,000	Aa3/A+/--	4.300%	5/22/2028	+25	25 bps
5/18/2026	Merck	Sr Notes	$500	Aa3/A+/--	3.935%	5/22/2028	SOFR+37	25 bps

Most Recent Healthcare High-Yield Issuances ($MM)

Date	Issuer	Security	Size	Ratings	Coupon	Maturity	Spread	Price Talk
6/30/2026	Prestige Brands	Sr. Notes	$400	B1/BB-/NR	6.250%	7/15/2034	190 bps	6.375% area
6/17/2026	Gentiva	Sr. Sec. Notes	$500	B3/B-/NR	8.000%	6/30/2031	382 bps	8.125%-8.375%

Most Recent Healthcare Leveraged Loan Issuances ($MM)

Date	Issuer	Ownership	Corp. Ratings	Use of Proceeds	Size	Pricing	Yield
3/19/2026	Select Medical Corporation	WCAS	B1 / B+	LBO	$100	SOFR+300, 0% @ 99	6.925%
2/5/2026	Resonetics LLC	Carlyle Group	B3 / B-	Acquisition	$220	SOFR+275, 0.75% @ 99.25	6.606%
1/29/2026	TEAM Services Group	General Atlantic	B2 / B-	LBO	$700	SOFR+525, 0% @ 99	9.171%
1/29/2026	Dechra Pharmaceuticals	EQT Partners	B2 / B-	Repricing	$834	SOFR+275, 0% @ 100	6.421%

Most Recent Healthcare Pro Rata Issuances ($MM)

Date	Issuer	Ownership	Ratings	Use of Proceeds	Size	Pricing (in bps)	Financial Covenants
5/15/2026	VSP Optical Group, Inc.*	Private	Baa2 / NR	Refinancing	$1,500mm 5-year Revolver $1,375mm 5-year Term Loan A	Ratings-based Grid SOFR+87.5-150 Opens at SOFR+100	Max. Net Leverage Ratio: 3.75x w/ step-up to 4.25x Min. Interest Coverage Ratio: 2.50x
2/12/2026	Alkermes	Public	Ba2 / BB	Acquisition	$750mm 5-year Term Loan A	Leverage-based Grid SOFR+250-300 Opens at SOFR+275	Max. Secured Net Leverage Ratio: 4.25x Min. Interest Coverage Ratio: 2.50x

Sources: Capital IQ, Mergermarket, and press releases

** Denotes Cain Brothers/KeyBanc Capital Markets participation*

Transaction occurred over the past week

Public Finance Market

Market Overview

- The yield on the benchmark 10-year U.S. Treasury Note increased 7 bps week-over-week, closing at 4.56% on Friday. 10-year MMD increased 7 bps week-over-week.
- Healthcare Public Issuance in 2025 increased 34% vs 2024. YTD 2026 Issuance through July 10th was 10% higher than YTD 2025 through the end of July.
- Muni bond funds gained $1.4 BN and high yield funds gained $109 MM for the week ended July 10th

MMD & UST Yield Curve



Weekly New Issue Volume *($MM)*



Benchmark Yields

Treasury Yields			MMD Yields			Ratio
Yr	Yield	Δ (W/W)	Yr	Yield	Δ (W/W)	MMD/ UST
2	4.21%	7 bps	2	2.37%	2 bps	56%
10	4.56%	7 bps	10	3.03%	7 bps	66%
30	5.06%	8 bps	30	4.27%	7 bps	84%

Healthcare Public Issuance Overview



Recent Healthcare Public Issuance

Healthcare Public Issuance										
Borrower/Enhancement	**Par (000s)**	**State**	**Issuer**	**Tax Status**	**LT Ratings (M/S/F)**	**Final Mat.**	**Call, Put or Reprice***	**Final Mat. Cpn.**	**YTW**	**YTM**
Recent Pricings, Week of 7/6										
Hartford Healthcare Energy Project	212,060	CT	CSHEFAR	TE	NR / A / NR	2056	2036(C)	5.50%	4.67%	5.07%
Hartford Healthcare Energy Project	137,940	CT	CSHEFAR	TAX	NR / A / NR	2036	MWC	5.49%	5.49%	N/A
Inspira Health Obligated Group	102,850	NJ	NJSHCFF	TE	NR / NR / NR	2046	2027(C)	6.25%	6.25%	N/A
Exp. Pricings, Week of 7/13										
Norton Healthcare	503,960	KY	LJCMG	TE	NR / A / A+	-	-	-	-	-
Lakeland Regional HS	124,430	FL	CLF	TE	A2 / NR / NR	-	-	-	-	-
Carolina Village	45,875	NC	NCMCC	TE	NR / NR / NR	-	-	-	-	-

Sources: Bloomberg, TM3
** Denotes Cain Brothers/KeyBanc Capital Markets participation*
NC = No Call, MWC = Make Whole Call, (C) = Par Call, (P) = 1st Put, (R) = Reprice Date

Relevant News

[ACO REACH Participants Generated Nearly $1B In 2024 Savings: CMS]

Fierce Healthcare | July 10, 2026

Participants in the ACO REACH program generated nearly $1 billion in savings in 2024, according to new performance data from the Trump administration.

Pharma Execs Look Back On The First Half Of 2026

Healthcare Brew | July 6, 2026

Between the continued rise of GLP-1s, the Trump Administration pushing psychedelic medicine closer to a reality, and battles over the 340B drug discount program, pharma companies have had a busy 2026 so far.

OB-GYN Pay Overhaul Spells Changes For Maternal Care

Axios | July 13, 2026

A major change to how OB-GYNs are paid is coming, bringing the potential for improved maternal health — but also higher costs. Why it matters: The U.S. has the highest maternal mortality rate among peer countries, and obstetrics units across the country have been closing in recent years due to staffing shortages and low margins.

US Health Watchdog Expects $5.56 Billion In Recoveries And Savings

Reuters | July 13, 2026

The federal watchdog for the U.S. health department generated $5.56 billion in expected recoveries and projected savings over six months and barred 1,212 individuals and companies from federal programs, it said on Monday, even as its overall enforcement activity fell to the lowest level in two years.

'Obsolete, Outdated, Excessively Burdensome': Ahead Of Potential August CMS Deregulation Rule, Nursing Homes Call For Reform

Skilled Nursing News | July 10, 2026

Ahead of a potential CMS proposed rule aimed at reducing administrative burdens across health care – including nursing homes – that could be released in August, providers are urging the agency to standardize surveyor training, Medicare medical reviews and Minimum Data Set requirements.

Feds Push Back HIPAA Security Rule Overhaul To July 2027

Fierce Healthcare | July 10, 2026

Federal regulators have delayed a major overhaul of the Health Insurance Portability and Accountability Act (HIPAA) Security Rule, pushing back final action on the rule by a year.

Disclaimer

Industry Insights is compiled weekly by Cain Brothers, a division of KeyBanc Capital Markets, 1301 Avenue of the Americas, 37th Floor, New York, NY 10019; Ph: (212) 869-5600. To receive our Industry Insights email, please subscribe at key.com/newsletters. For questions regarding Industry Insights, please email rgruber@cainbrothers.com.

“Cain Brothers, a division of KeyBanc Capital Markets” is a trade name of KeyBanc Capital Markets Inc., Member FINRA/SIPC. KeyBanc Capital Markets Inc. and KeyBank National Association ("KeyBank N.A.") are separate, but affiliated companies. Securities products and services are offered by KeyBanc Capital Markets Inc. and its licensed securities representatives. Banking products and services are offered by KeyBank N.A.

This report was not issued by our research department. The information contained in this report has been obtained from sources deemed to be reliable but is not represented to be complete, and it should not be relied upon as such. This report does not purport to be a complete analysis of any security, issuer, or industry and is not an offer or a solicitation of an offer to buy or sell any securities. This report is prepared for general information purposes only.

Please read our complete KeyBanc Capital Markets disclosure statement.

CAIN BROTHERS
A division of
KeyBanc Capital Markets

July 29, 2026

Industry Insights

Healthcare Market Report

Banker Commentary:

Expanding Access to Mental Health Services: Addressing Barriers to Care

Banker Commentary

Contents

Expanding Access to Mental Health Services: Addressing Barriers to Care

Banker Commentary by Erika Haanpaa

Early intervention in healthcare saves costs and improves outcomes. That's no less true for behavioral and mental health than any other area of healthcare. Of course, in order to intervene, one must have access to quality care. Yet, for many, access remains limited as reimbursement lags and other barriers persist.

One such barrier for patients with mental illnesses and substance use disorders (SUD) covered by Medicaid has been the Institutions for Mental Disease (IMD) payment exclusion, severely limiting access to inpatient and residential treatment services for adults. Historically, federal law has excluded Medicaid payments for adult services in IMDs, which are behavioral treatment facilities with more than 16 beds. In recent years, programs have been developed to improve access and allow for coverage in certain situations, including Section 1115 IMD waivers. Since the SUD IMD waiver program launched in 2015, 38 states have adopted waivers, and as of April, six states have completed evaluations of the program.

KFF recently published an article that highlights some of the initial results from California, Indiana, New Hampshire, Utah, Washington, and Massachusetts. While the results and methods varied by state, some consistent themes emerged in the evaluations. More patients were diagnosed with SUD and more patients received treatment, including in inpatient/residential facilities. Additionally, states showed declines in SUD-related emergency department utilization. Though there were improvements in treatment and ED utilization, the states also identified consistent challenges limiting access, such as workforce shortages and burdensome administrative requirements that may have discouraged provider participation in the program.

Provider participation in public and private insurance programs remains a challenge to access as the demand for services continues to grow. According to a 2024 survey of psychologists, 66% were in network with any plan, of which 58% accepted private insurance, and 18% participated in managed Medicaid, while only 16% participated in traditional fee-for-service Medicaid programs. The primary reasons for not participating in plans were insufficient reimbursement rates and administrative burdens such as preauthorization requirements, audits, etc. Similarly, multiple studies have shown that the availability for in-network psychiatry services is limited, particularly for Medicaid patients.

Higher rates can lead to increased participation to improve access and reduce overall healthcare costs. A recent article in the American Journal of Managed Care reviewed differences in healthcare utilization for patients with Serious Mental Illness across states with high and low Medicaid reimbursement rates for psychiatric services. Unsurprisingly, it found that the covered patients in high-reimbursement states were less likely to have emergency department and inpatient visits and had 24% lower overall healthcare costs as well as 19% lower psychiatric-specific costs annually compared to patients in low-reimbursement states.

One of the challenges with such studies is that the administration of programs varies significantly state to state, and a broader variety of providers may offer mental healthcare services across different settings. The authors clearly state that it's an observed association that does not imply causality, but the evidence (and common sense) does suggest that higher rates can lead to greater participation and better outcomes.

On that front, nearly every state has made some effort to improve access to mental health services via rate increases over the past several years, with some adopting broad-based rate increases, others more targeted approaches, and some linking rates to Medicare fee schedules. It makes sense, and they should continue to prioritize these efforts to incentivize provider participation in the programs. It is not clear if these increases will be enough to move the needle in terms of participation given the supply-demand imbalance, particularly in states where the rates remain meaningfully below those providers can receive from other sources, including commercial insurance and private pay.

M&A Activity

Selected Recent Healthcare Transactions *($MM)*

Date	Target Name	Acquirer	EV	Enterprise Value / LTM Rev.	Enterprise Value / LTM EBITDA	Description
7/27/2026	KMM Group	RS2 Healthcare Partners (fka Riverside Partners)	NA	NA	NA	Vertically integrated precision contract manufacturer
7/26/2026	Apex Vascular	US Heart & Vascular (Ares and Rubicon Founders)	NA	NA	NA	Vascular surgery and vein center
7/26/2026	MAS Medical Staffing	Care Career	NA	NA	NA	Healthcare workforce organization
7/24/2026	Apex Infusion Partners	SkyKnight Capital	NA	NA	NA	Omnichannel infusion services provider
7/22/2026	First Choice Healthcare	Westin Acquisition	$650			Next-generation healthcare and wellness platform
7/21/2026	Northstar Dental Partners	Dentalcorp (GTCR)	NA	NA	NA	Dental group based in Florida
7/21/2026	Janus Healthcare	Mindoula (Equality Asset Management)	NA	NA	NA	Psychiatric collaborative care company
7/21/2026	Valera Health	Mindoula (Equality Asset Management)	NA	NA	NA	Virtual mental health platform
7/20/2026	Strive Medical (NMS Capital)*	Cardinal Health	NA	NA	NA	Multi-specialty supply provider with a focus on urology
7/20/2026	AdaptHealth's Diabetes Health Unit	Cardinal Health	NA	NA	NA	Centralized, mail-order, direct-to-patient model for diabetes supplies
7/17/2026	MAKRAF IME	PAX Health (HCAP Partners)	NA	NA	NA	Psychology and neuropsychology independent medical examination provider group
7/15/2026	Concert (Deerfield Management and Relevance Capital)	Lyric (TPG, Ares and Symphony Ventures)	NA	NA	NA	Precision health payment accuracy platform
7/15/2026	Select Dental Management (majority stake)	Guardian Dentistry Partners	NA	NA	NA	Dental partnership organization
7/14/2026	Dialog Health	SpinSci (Aldrich Capital Partners)	NA	NA	NA	Patient communication platform for health systems, health plans, and ambulatory surgery centers
7/14/2026	StatLab Medical Products (Linden Capital Partners and Audax Private Equity)	Leica Biosystems	NA	NA	NA	Developer and manufacturer of anatomical pathology products
7/14/2026	VitalRADS	Zoetis	NA	NA	NA	Veterinary teleradiology services platform
7/9/2026	Canadian Dental Labs	CenterGate Capital	NA	NA	NA	Manufacturer of dental prosthetics and orthodontic appliances
7/9/2026	Empower Emergency Physicians	Emergency Care Partners (Varsity Healthcare Partners, Regal Healthcare Capital Partners)	NA	NA	NA	Independent emergency medicine group
7/7/2026	Corza Medical's Biosurgery Business Unit (GTCR)	EQT	NA	NA	NA	Biologic and surgical products

Sources: Capital IQ, Merger market, and press releases
** Denotes Cain Brothers/KeyBanc Capital Markets participation*
Transaction occurred the past week

Private Placement Activity

Selected Recent Healthcare Transactions *($MM)*

Date	Company	Investor(s)	Type	Amount	Description
7/23/2026	Candid Health	Sixth Street Growth (lead), Oak HC/FT, 8VC, and Y Combinator	Series D	$120	Developer of an autonomous revenue cycle automation platform for healthcare providers
7/16/2026	Bunkerhill Health	Khosla Ventures (lead), Sequoia Capital, Felicis, Optum Ventures and Y Combinator	Series B	$25	Provider of agentic AI for health systems
7/15/2026	Neko Health	Lightspeed Venture Partners (lead), O.G. Venture Partners (co-lead), Atomico, General Catalyst and Lakestar, Liberty City Ventures, Positive Sum, and BDT & MSD	Series C	$700	Preventive healthcare technology company focused on AI-powered full-body health scans and early disease detection
7/15/2026	Oura	Eli Lilly	Equity	Undisclosed	Smart wearable devices that monitor sleep, activity, recovery, stress and other biometric health data
7/13/2026	Corner Health	Oak HC/FT (lead), First Round Capital and Zigg Capital	Series A	$25	Platform that equips nurse practitioners to launch and scale their own independent primary care practices
7/8/2026	Pearl Health	Andreessen Horowitz (equity lead), Viking Global Investors, AlleyCorp, Ulysses Capital, Trinity Capital (debt)	Equity and Debt	$110	AI-powered predictive insights and financial modeling platform for primary care providers
7/7/2026	Pediatrica Health Group	Valspring Capital (lead), M33 Growth	Series B	$28	multi-site pediatric primary care organization dedicated to delivering Next Generation CareSM to families
6/25/2026	Assort Health	Menlo Ventures (lead)	Series C	$120 $1.2 bn valuation	AI agents platform for the patient journey
6/23/2026	Cadence	Spark Capital (lead), Thrive Capital, General Catalyst, Coatue, B Capital, Corewell Health Ventures, Memorial Hermann, and Duke Health	Series C	$100	Digital health company for patients with chronic conditions
6/22/2026	Ensemble Health Partners	Thoreau Group	Strategic Growth	Undisclosed	Revenue cycle management platform for healthcare companies
6/17/2026	InStride	Echo Health Ventures and FMZ Ventures (co-leads), .406 Ventures, Valtruis, General Catalyst, and Mass General Brigham Ventures	Series C	$30	Insurance-covered specialty program for young people living with complex anxiety, OCD, and related disorders
6/15/2026	Centauri Health (Abry Partners)	Neuberger and Apollo S3 (co-leads)	Continuation Vehicle	$780	Healthcare technology company that delivers data-driven solutions to U.S. health plans
6/8/2026	HST Pathways (Bain Capital and Nexxus Holdings)	Novo Holdings	Strategic	Undisclosed	Cloud-based software platform for ambulatory surgery centers
6/8/2026	Stepful	Oak HC/FT (lead), Foresite Capital, Hearst Ventures, Citi Impact Fund, SemperVirens, Y Combinator, Intermountain Health, and ECMC Education Impact Fund	Series C	$55	AI-powered healthcare workforce training platform
6/3/2026	Collate	Redpoint Ventures (lead), First Round and Conviction Partners	Undisclosed	$95 $1 bn valuation	Platform using AI to automate life sciences paperwork
6/2/2026	Adaptive Innovations	Felicis and Bain Capital Ventures (co-leads), Optum Ventures, Sunflower Capital, Conviction, BoxGroup, SV Angels, Dorm Room Fund, Constellation	Series A	$50	AI native healthcare firm
6/1/2026	42 North	Audax Private Equity and Farallon Capital	Preferred Equity	$80	Dental service organization
5/28/2026	Garner Health	Index Ventures (lead), Kleiner Perkins, Redpoint, Thrive, Sequoia, Founders Fund, and Kaiser Permanente Ventures	Series E	$100 $3 bn valuation	Digital platform provider for patients finding healthcare providers
5/19/2026	Commure	General Catalyst (lead), Sequoia Capital, Morgan Stanley and Kirkland & Ellis	Series C	$70 $7 bn valuation	AI infrastructure platform for health systems
5/19/2026	Nourish	Menlo Ventures (lead), Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures, Y Combinator, BoxGroup, Atomico, Daybreak, and Operator Partners	Series C	$100 $2 bn valuation	Dietitian-led metabolic health clinic
5/19/2026	Vi	General Atlantic, Revelstoke, 1902 Capital and Square Peg (co-leads)	Undisclosed	$145 $2 bn valuation	AI-enabled healthcare technology platform

Sources: Capital IQ, Merger market, and press releases
** Denotes Cain Brothers/KeyBanc Capital Markets participation*
Transaction occurred over the past week

Equity Capital Markets

Market Overview

- ECM issuance dipped last week amidst continued geopolitical conflict in the Middle East and the kick-off of earnings season
  - Last week: 1 IPOs; 4 follow-ons; 0 converts
- Two sponsor backed IPOs are on the road for pricing this week, the largest being Blackstone-backed Jersey Mike's which is seeking to raise $1.0 BN. The IPO market is heading into a slower seasonal period in August, but an active pipeline of issuers awaits a highly productive September window
- Follow-on issuance will likely pick-up as issuers get through earnings-related blackout periods and stocks remain just off all-time highs

U.S. ECM Offerings *(LTM; IPOs, Follow-ons & Converts)*



ECM Activity *(Last 4 Weeks & YoY)*

	2026 - Last 4 Weeks			2025 - Last 4 Weeks		
	Vol ($MM)	# Deals	% Share	Vol ($MM)	# Deals	% Share
IPO	1,862	5	11%	2,426	5	18%
CONV	3,601	8	22%	5,056	7	37%
FO	11,282	21	67%	6,044	19	45%
Total	16,745	34	100%	13,526	31	100%

	2026 YTD			2025 YTD		
	Vol ($MM)	# Deals	% Share	Vol ($MM)	# Deals	% Share
IPO	125,865	60	39%	16,570	33	12%
CONV	85,009	80	26%	44,655	50	33%
FO	114,708	217	35%	75,540	139	55%
Total	325,582	357	100%	136,765	222	100%

IPO & Follow-on 1-Week Performance *(LTM)*



Most Recent Healthcare Initial Public Offerings *($MM)*

Issuer Information				Deal Sizing				Pricing		Performance	
Pricing Date	Company	Sector	Ticker	Deal Value ($MM)	Market Cap ($MM)	Deal as % of Mkt. Cap	% Primary	Offer Price	Final Range	1-Day	1-Week
5/12/2026	GMR Solutions	Healthcare Services	GMRS	$478.7	$3,347.2	14.3%	100.0%	$15.00	$22.00 - $25.00	(6.8%)	(19.5%)
5/7/2026	Mobia Medical	Medical Products	MOBI	$150.0	$496.3	30.2%	100.0%	$15.00	$14.00 - $16.00	(21.7%)	(19.7%)
4/16/2026	Alamar Biosciences	Diagnostics	ALMR	$219.9	$1,130.9	19.4%	100.0%	$17.00	$15.00 - $17.00	29.4%	42.8%
3/5/2026	MiniMed Group	Medical Products	MMED	$560.0	$5,616.3	10.0%	100.0%	$20.00	$26.00 - $30.00	(7.6%)	(17.4%)
12/16/2025	Medline	Medical Products	MDLN	$7,204.7	$38,097.8	18.9%	72.1%	$29.00	$26.00 - $30.00	41.4%	50.5%

Most Recent Healthcare Follow-on Offerings *($MM)*

Issuer Information					Deal Sizing				Pricing	Performance	
Pricing Date	Company	Sector	Deal Type	Ticker	Deal Value ($MM)	Market Cap ($MM)	Deal as % of Mkt. Cap	% Primary	Discount to File	1-Day	1-Week
6/16/2026	Sophia Genetics	Diagnositcs	Marketed	SOPH	$57.5	$405.8	14.2%	100.0%	(3.7%)	10.3%	10.1%
6/5/2026	Nyxoah	Medical Products	Marketed	NYXH	$95.0	$287.8	33.0%	100.0%	(40.3%)	(19.2%)	(19.2%)
5/21/2026	Medline	Medical Products	Marketed	MDLN	$2,684.5	$48,737.8	5.5%	0.0%	(1.9%)	0.0%	(0.5%)
5/11/2026	Sotera Health Group	Medical Products	Bought	SHC	$486.2	$4,400.1	11.0%	0.0%	(1.0%)	2.4%	(0.5%)
5/7/2026	LifeStance Health Group	Healthcare Services	Bought	LFST	$236.4	$3,432.3	6.9%	0.0%	(7.9%)	(5.5%)	(0.5%)

Most Recent Healthcare Convertible Debt Offerings *($MM)*

Issuer Information				Deal Sizing			Pricing	
Pricing Date	Company	Sector	Ticker	Deal Value ($MM)	Market Cap ($MM)	Deal as % of Mkt. Cap	Coupon	Premium
6/17/2026	Adaptive Biotechnologies	Diagnostics	ADPT	$345.0	$2,756.0	12.5%	0.00%	40.00%
6/17/2026	NeoGenomics	Healthcare Services	NEO	$316.3	$1,365.9	3.2%	0.75%	35.00%
2/24/2026	Tandem Diabetes Care	Healthcare Products	TNDM	$300.0	$1,838.0	16.3%	0.00%	37.50%
11/4/2025	Guardant Health	Diagnostics	GH	$402.5	$12,745.9	3.2%	0.00%	35.00%
9/16/2025	Oscar Health	Health Insurance	OSCR	$410.0	$4,842.8	8.5%	2.25%	32.50%

Sources: Bloomberg, Capital IQ, Dealogic, and Press Releases

*Note: Transactions include IPOs, follow-ons (including bought deals) and convertible offerings of $25MM or more priced on a U.S.-based exchange; Price performance includes both marketed and bought deal follow-ons; * denotes Cain Brothers / KBCM transaction; excludes SPACs and fixed price IPOs*

Transaction occurred the past week

Public Equity Indices

Equity Indices (as of July 24, 2026)

Index	Wk Open	Wk Close	Returns 52 Week	Returns Weekly
DJIA	52,146	51,947	16.2%	(0.4%)
S&P 500	7,458	7,412	16.5%	(0.6%)
NASDAQ	25,520	24,976	18.6%	(2.1%)
Russell 2000	2,962	2,930	30.1%	(1.1%)
NYSE Healthcare	28,057	28,473	19.4%	1.5%

Cain Brothers Indicies	Returns 52 Week	Returns Weekly
Acute Care	7.8%	5.5%
Alternate Site Services	6.3%	1.3%
Diagnostics	7.3%	0.8%
Distribution	15.9%	(0.0%)
Healthcare IT	(27.1%)	(3.0%)
Healthcare REITs	61.7%	3.7%
Managed Care	42.0%	(1.0%)
Medical Technology	(7.6%)	0.6%
Outsourced Services	67.0%	(4.7%)
Pharma Services	0.7%	(0.7%)
Pharmacy	78.0%	0.2%
Primary Care	64.8%	(17.5%)
Post-Acute Care Services	53.1%	1.2%
Post-Acute Care Facilities	52.0%	0.9%

Cain Brothers Healthcare Indices (1YR Performance)



Sources: Cain Brothers, Bloomberg, Capital IQ

High Grade, High Yield & Leveraged Loan Market

Market Summary

High Grade

- The IG primary market saw a slow week last week as only 13 issuers came to market for $14.0 BN in volume amid a heavy rise in base rates.

High Yield

- As oil prices and Treasury yields spiked amid intensifying Middle East tension, the primary market remained active; total weekly volume of $6.2 BN was buoyed by a large AI-capex financing totaling $3.5 BN for Galaxy Helios Data Centers.

Term Loan B Market

- CLO issuance has slowed significantly amidst the volatile backdrop after a strong start to the year.

HY Index Yield & Spread *(YTD)*



Weekly New Issue Volume *($BN)*



New-Issue Clearing Yields[1] *($MM)*

Double-B Issuers	1Q26	2Q26	30-Day Rolling Average 07/24/26
Ba1	S+210 / 6.2%	S+214 / 5.8%	S+250 / 6.2%
Ba2	S+239 / 6.5%	S+190 / 5.6%	S+188 / 5.6%
Ba3	S+220 / 6.2%	S+238 / 6.1%	S+228 / 6.0%
Single-B Issuers	**1Q26**	**2Q26**	**30-Day Rolling Average 07/24/26**
B1	S+284 / 6.6%	S+251 / 6.2%	S+264 / 6.7%
B2	S+322 / 7.0%	S+325 / 7.0%	S+338 / 7.2%
B3	S+351 / 7.3%	S+404 / 7.9%	S+389 / 7.8%

Most Recent Healthcare High-Grade Issuances *($MM)*

Date	Issuer	Security	Size	Ratings	Coupon	Maturity	Spread	IPT-Pricing
7/15/2026	Bayer US Finance	Sr Notes	$1,000	Baa2 / BBB / BBB	5.125%	7/20/2031	+87	28 bps
7/15/2026	Bayer US Finance	Sr Notes	$750	Baa2 / BBB / BBB	5.375%	7/20/2033	+102	28 bps
7/15/2026	Bayer US Finance	Sr Notes	$1,500	Baa2 / BBB / BBB	5.625%	7/20/2036	+115	25 bps

Most Recent Healthcare High-Yield Issuances *($MM)*

Date	Issuer	Security	Size	Ratings	Coupon	Maturity	Spread	Price Talk
6/30/2026	Prestige Brands	Sr. Notes	$400	B1/BB-/NR	6.250%	7/15/2034	190 bps	6.375% area
6/17/2026	Gentiva	Sr. Sec. Notes	$500	B3/B-/NR	8.000%	6/30/2031	382 bps	8.125%-8.375%

Most Recent Healthcare Leveraged Loan Issuances *($MM)*

Date	Issuer	Ownership	Corp. Ratings	Use of Proceeds	Size	Pricing	Yield
3/19/2026	Select Medical Corporation	WCAS	B1 / B+	LBO	$100	SOFR+300, 0% @ 99	6.925%
2/5/2026	Resonetics LLC	Carlyle Group	B3 / B-	Acquisition	$220	SOFR+275, 0.75% @ 99.25	6.606%
1/29/2026	TEAM Services Group	General Atlantic	B2 / B-	LBO	$700	SOFR+525, 0% @ 99	9.171%
1/29/2026	Dechra Pharmaceuticals	EQT Partners	B2 / B-	Repricing	$834	SOFR+275, 0% @ 100	6.421%

Most Recent Healthcare Pro Rata Issuances *($MM)*

Date	Issuer	Ownership	Ratings	Use of Proceeds	Size	Pricing (in bps)	Financial Covenants
5/15/2026	VSP Optical Group, Inc.*	Private	Baa2 / NR	Refinancing	$1,500mm 5-year Revolver $1,375mm 5-year Term Loan A	Ratings-based Grid SOFR+87.5-150 Opens at SOFR+100	Max. Net Leverage Ratio: 3.75x w/ step-up to 4.25x Min. Interest Coverage Ratio: 2.50x
2/12/2026	Alkermes	Public	Ba2 / BB	Acquisition	$750mm 5-year Term Loan A	Leverage-based Grid SOFR+250-300 Opens at SOFR+275	Max. Secured Net Leverage Ratio: 4.25x Min. Interest Coverage Ratio: 2.50x

CAIN BROTHERS
A division of KeyBanc Capital Markets

Sources: Capital IQ, Mergermarket, and press releases
** Denotes Cain Brothers/KeyBanc Capital Markets participation*
Transaction occurred over the past week

Public Finance Market

Market Overview

- The yield on the benchmark 10-year U.S. Treasury Note increased 14 bps week-over-week, closing at 4.69% on Friday. 10-year MMD increased 22 bps week-over-week.
- Healthcare Public Issuance in 2025 increased 34% vs 2024. YTD 2026 Issuance through July 24th was 11% higher than YTD 2025 through the end of July.
- Muni bond funds gained $174 MM and high yield funds lost $91 million for the week ended July 24th.

MMD & UST Yield Curve



Weekly New Issue Volume *($MM)*



Benchmark Yields

Treasury Yields			MMD Yields			Ratio
Yr	Yield	Δ (W/W)	Yr	Yield	Δ (W/W)	MMD/ UST
2	4.33%	15 bps	2	2.61%	18 bps	60%
10	4.69%	14 bps	10	3.36%	22 bps	72%
30	5.16%	10 bps	30	4.52%	19 bps	88%

Healthcare Public Issuance Overview



Recent Healthcare Public Issuance

Healthcare Public Issuance										
Borrower/Enhancement	**Par (000s)**	**State**	**Issuer**	**Tax Status**	**LT Ratings (M/S/F)**	**Final Mat.**	**Call, Put or Reprice***	**Final Mat. Cpn.**	**YTW**	**YTM**
Recent Pricings, Week of 7/20										
Univ. of Penn. Health System	138,535	PA	PHEFA	TE	Aa3 / AA / NR	2042	2037(C)	5.00%	4.33%	4.50%
Univ. of Penn. Health System	94,150	PA	PHEFA	TE	Aa3 / AA / NR	2042	2036(C)	5.00%	3.94%	4.25%
LSP Children's Hosp. at Stan.	138,405	CA	CHFFA	TE	A1 / A+ / AA-	2047	2036(C)	5.00%	4.16%	4.49%
Princeton Healthcare System	116,230	NJ	NJHCFFA	TE	Aa3 / AA / NR	2039	2036(C)	5.00%	3.67%	3.91%
Advocate Aurora Healthcare	39,060	WI	WHEFA	TE	NR / AA / NR	2047	2036(P)	5.00%	3.74%	4.26%
Advocate Aurora Health CG	37,280	WI	WHEFA	TE	NR / AA / NR	2054	2034(P)	5.00%	3.56%	4.40%
San Luis Community Hospital	20,600	AZ	SLAIDAH	TE	NR / NR / NR	2033	NC	7.50%	7.69%	N/A
Exp. Pricings, Week of 7/27										
QCF Adv. Behavioral Health*	**612,510**	**NJ**	**NJEDA**	**TE**	**NR / NR / NR**	**-**	**-**	**-**	**-**	**-**
AdventHealth Obligated Group	1,028,580	CO	CHFA	TE	Aa2 / AA / AA	-	-	-	-	-
Maine Sustainable Energy Partner	120,615	ME	NFA	TE	NR / A+ / NR	-	-	-	-	-
SAC Health System	86,825	CA	CMFA	TE	NR / NR / BBB	-	-	-	-	-
Peapack Senior Living Project	83,235	NJ	PFA	TE	NR / NR / NR	-	-	-	-	-
Vivera Fairfield Project	38,890	OH	LPA	TE	NR / NR / NR	-	-	-	-	-
Green Oaks of Walnut Creek	34,020	OH	OHFA	TE	NR / NR / NR	-	-	-	-	-

Sources: Bloomberg, TM3
** Denotes Cain Brothers/KeyBanc Capital Markets participation*
NC = No Call, MWC = Make Whole Call, (C) = Par Call, (P) = 1st Put, (R) = Reprice Date

Relevant News

[CMS Moves To Codify Limits On Medicaid Provider Taxes]

Healthcare Dive | July 22, 2026

The rule is meant to prevent states from guaranteeing that providers will be refunded for their tax costs, and should save Washington $246 billion over the next decade, regulators said.

[Home-Based Care Advocates Push For Permanent Medicare Telehealth Legislation]

Home Health Care News | July 24, 2026

Over 200 health care organizations have come together to push Congress to enact permanent Medicare telehealth coverage, without which home health appointments are at risk of delays and providers could face increased administrative and billing challenges..

[Industry Voices - Rural Healthcare's New Model Is Taking Shape]

Fierce Healthcare | July 24, 2026

For millions of Americans, where you live is quietly becoming one of the biggest predictors of lifespan. In rural communities across the country, the healthcare system is undergoing a rapid and irreversible shift..

[Logistics Giants Are Racing To Keep Up With Healthcare Boom As GLP-1s Highlight Need For Cold Storage]

Msn.com | July 25, 2026

As demand rises for specialized medications like GLP-1s, logistics companies including UPS and FedEx are adapting their strategies to be able to better ship and store those pharmaceuticals..

[Trump Admin Demands Hospitals Share Emergency Room Records]

Fierce Healthcare | July 27, 2026

A tiny federal agency tasked with protecting the public from injuries caused by lawn mowers and coffeemakers is demanding that some of the nation's biggest health systems turn over detailed, personally identifiable medical records of all patients who seek help at their emergency rooms.

[Pharmacy Advocacy Group Urges 340B Oversight Shift To CMS]

Becker's Hospital Review | July 27, 2026

ADAP Advocacy has called for oversight of the 340B Drug Pricing Program to move from HRSA to CMS. The advocacy organization said the shift would address what it described as longstanding gaps in regulatory oversight and enforcement, according to a July 27 news release.

Disclaimer

Industry Insights is compiled weekly by Cain Brothers, a division of KeyBanc Capital Markets, 1301 Avenue of the Americas, 37th Floor, New York, NY 10019; Ph: (212) 869-5600. To receive our Industry Insights email, please subscribe at key.com/newsletters. For questions regarding Industry Insights, please email rgruber@cainbrothers.com.

"Cain Brothers, a division of KeyBanc Capital Markets" is a trade name of KeyBanc Capital Markets Inc., Member FINRA/SIPC. KeyBanc Capital Markets Inc. and KeyBank National Association ("KeyBank N.A.") are separate, but affiliated companies. Securities products and services are offered by KeyBanc Capital Markets Inc. and its licensed securities representatives. Banking products and services are offered by KeyBank N.A.

This report was not issued by our research department. The information contained in this report has been obtained from sources deemed to be reliable but is not represented to be complete, and it should not be relied upon as such. This report does not purport to be a complete analysis of any security, issuer, or industry and is not an offer or a solicitation of an offer to buy or sell any securities. This report is prepared for general information purposes only.

Please read our complete KeyBanc Capital Markets disclosure statement.